Selma Tobudic - Concepedia

Author

Selma Tobudic

Medical University of Vienna ORCID

Also Known As

H Burgmann, Heinz Burgmann, Professor Selma Tobudic, S Tobudic, S. Tobudic, Selma Tobudic, Tobudic, Selma

103

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

Medical University of Vienna Vienna General Hospital Jena University Hospital Hospital for Tropical Diseases

About

Selma Tobudic is an author at Medical University of Vienna specializing in medicine, infection control, and antimicrobial resistance.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	17	613
2	Health Sciences	5	5	304
3	Public Health	4	4	113
4	Management	1	1	52
5	Nursing	1	1	52

Selma Tobudic

Publications

Citations

H-Index

Page 1

	Year	Citations
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity Daniel Mrak, Selma Tobudic, Maximilian Koblischke, Annals of the Rheumatic Diseases	2021	244
Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna Selma Tobudic, Christina Forstner, Heinz Burgmann, Clinical Infectious Diseases Antimicrobial SusceptibilityHealth SciencesAntibiotic AdjuvantGram-positive Infective EndocarditisHealthcare-associated Infection	2018	180
In vitro activity of antifungal combinations against Candida albicans biofilms Selma Tobudic, Christina Kratzer, Andrea Lassnigg, Journal of Antimicrobial Chemotherapy	2009	107
Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study Nicole Harrison, Margit Mitterbauer, Selma Tobudic, BMC Infectious Diseases	2015	73
Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations Maximilian J. Mair, J.M. Berger, Anna S. Berghoff, JAMA Oncology	2021	68
Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection Selma Tobudic, Christina Forstner, Heinz Burgmann, Infection	2019	63
Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial Michael Bonelli, Daniel Mrak, Selma Tobudic, Annals of the Rheumatic Diseases	2022	60
SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients – A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease Angelika Wagner, Erika Garner‐Spitzer, Anna‐Margarita Schötta, Frontiers in Immunology	2022	60
Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE) Daniela Knafl, Selma Tobudic, Serena Cheng, European Journal of Clinical Microbiology & Infectious Diseases	2016	58
Antifungal activity of amphotericin B, caspofungin and posaconazole on<i>Candida albicans</i>biofilms in intermediate and mature development phases Selma Tobudic, Andrea Lassnigg, Christina Kratzer, Mycoses	2009	57

Page 1